AGEN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability TurnaroundThe sharp TTM improvement shows meaningful commercial and earnings progress after several loss-making years. If collaboration revenue and milestone activity continue, this provides a stronger base for funding development and advancing oncology programs.
Focused Phase 3 StrategyConcentrating resources on a defined earlier-stage colon cancer opportunity may improve capital efficiency and execution. The planned Phase 3 program and supportive Phase 2 findings create a clearer development pathway toward potential future commercialization.
Lower Debt BurdenThe substantial debt reduction lowers near-term repayment pressure and improves the company’s financing flexibility relative to 2025. Although the balance sheet remains weak, reduced absolute debt can support continued investment in clinical development.
Bears Say
Persistent Cash BurnLarge recurring cash outflows indicate that operations and clinical development are not self-funding. Unless collaboration receipts or product-related economics improve, Agenus may need additional financing, potentially limiting strategic flexibility and shareholder returns.
Negative Shareholder EquityNegative equity reflects accumulated losses and a thin capital base, reducing financial resilience even after debt declined. It can increase refinancing and dilution risk while leaving the company more exposed to setbacks in clinical or partnership programs.
Equity-Linked Financing And Earnings VolatilityUsing shares to satisfy debt costs can dilute existing holders and signals constrained liquidity. In parallel, the latest profit rebound follows deep prior losses, so earnings quality and future revenue remain dependent on irregular financing and collaboration events.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Currently, no data Available
What is Agenus’s market cap?
Agenus’s market cap is CHF270.24M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Aug 06, 2026. The company reported -CHF0.008 earnings per share for the quarter, missing the consensus estimate of CHF0.037 by -CHF0.045.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is >-0.01.
How many shares outstanding does Agenus have?
Currently, no data Available
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -CHF0.008 in its last earnings report, missing expectations of CHF0.037. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in CH:AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF15.63 (― Upside)
CHF15.63 (― Upside)
Blogger Sentiment
Bullish
CH:AGEN Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.76%
Trailing 12-Months
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
―Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―